TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7851587
Drug: Low-dose GnRH-a
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GnRH-a (250 micrograms SC leuprolide acetate) and hMG with non-elevated LH (< 35 mIU/mL)
Study: 2184694
Drug: piritramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: piritramide 0.1 mg/kg
Study: 7387140
Drug: Netilmicin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 1.0 mg/kg
Study: 7387140
Drug: Gentamicin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.0 mg/kg
Study: 7387140
Drug: Netilmicin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin 2.5 mg/kg
Study: 7387140
Drug: Gentamicin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2.5 mg/kg
Study: 28634972
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment course with prednisone
Study: 28634972
Drug: 14-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day treatment course with prednisone
Study: 9852387
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 2 mg estradiol (E2) for 12 days, followed by 2 mg E2 and 1 mg norethisterone acetate for 10 days, then 1 mg E2 for 6 days, cyclically during 6 months.
Study: 8770316
Drug: L-arginine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (16 g i.v.)
Study: 2287058
Drug: BMY-28100 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMY-28100 (750 mg daily, divided into 3 administrations for at least 14 days)
Study: 2287058
Drug: CCL (cefaclor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCL (cefaclor, 1,500 mg daily, divided into 3 administrations for at least 14 days)
Study: 6169509
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (20% benzocaine)
Study: 26811055
Drug: Tablet-based game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based game (3 × 10 min)
Study: 22277140
Drug: Carvedilol controlled‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol controlled‐release plus lisinopril (C+L)
Study: 22277140
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus lisinopril (H+L)
Study: 17559737
Drug: Posaconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (200 mg once daily)
Study: 17559737
Drug: Phenytoin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (200 mg once daily)
Study: 17559737
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of posaconazole and phenytoin (both 200 mg once daily)
Study: 16299322
Drug: Nasal insufflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan (2 doses, 28 days apart)
Study: 16299322
Drug: Nasal insufflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan (1 dose)
Study: 16299322
Drug: Nasal insufflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal insufflation of MCP-CRM197 conjugate vaccine mixed with chitosan
Study: 16299322
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of MCP-CRM197 conjugate vaccine in alum
Study: 7697308
Drug: Active administration
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active administration of specific bacterial cultures in fermented milk
Study: 30975673
Drug: Urine CXCL10
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine CXCL10 monitoring with study biopsy for subclinical rejection and treatment per protocol.
Study: 22820612
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor-based regimen
Study: 17227324
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication treatment
Study: 17227324
Drug: Diet only
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet only treatment
Study: 11722955
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg leucine x kg(‐1) x d(‐1)
Study: 11722955
Drug: 22 mg
Normalized name: urea 0.22 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg leucine x kg(‐1) x d(‐1)
Study: 11722955
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg leucine x kg(‐1) x d(‐1)
Study: 11722955
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg leucine x kg(‐1) x d(‐1)
Study: 26696251
Drug: Single-dose rabbit
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rabbit anti-thymocyte globulin (SD-rATG) 6 mg/kg
Study: 26696251
Drug: Divided-dose rabbit
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided-dose rabbit anti-thymocyte globulin (DD-rATG) 1.5 mg/kg/dose
Study: 15684166
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg of sublingual misoprostol
Study: 12851519
Drug: PL (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL (equivalent to 100 mg isoflavone; n = 45)
Study: 10566461
Drug: Online vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online vaccine reminders
Study: 9093647
Drug: Xylocaine 10%
Normalized name: Xylocaine 10% Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine 10% spray
Study: 1910697
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (4 mg/kg of 4% lidocaine)
Study: 6293259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and irradiation
Study: 6293259
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment (irradiation)
Study: 6293259
Drug: Patients operated
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients operated upon after preoperative treatment
Study: 22313522
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and zeaxanthin supplements (Study 2)
Study: 22313522
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and zeaxanthin supplements
Study: 27704562
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg single oral dose
Study: 27704562
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg co-administered with Efavirenz 600 mg
Study: 24044461
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed 3 months after augmentation
Study: 24044461
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed 6 months after augmentation
Study: 19522571
Drug: Methylprednisolone 16
Normalized name: methylprednisolone 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 16 mg/kg intravenously every day for 3 days
Study: 18546838
Drug: Epithalamin pineal
Normalized name: Bos taurus pineal gland preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epithalamin pineal gland peptide medication
Study: 15793365
Drug: Genotypic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic resistance testing alone (G arm)
Study: 15793365
Drug: Genotypic plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic plus phenotypic testing (G + P arm)
Study: 12418499
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg SAMe/d orally for 6 weeks
Study: 12418499
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg SAMe/d intramuscularly for 4 weeks
Study: 12418499
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg imipramine/d orally
Study: 10386277
Drug: Needle administration
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle administration
Study: 6641536
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg gentamycin intramuscularly
Study: 6641536
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g amoxicillin orally
Study: 30928207
Drug: Sham-rTMS (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-rTMS (sham treatment)
Study: 26362661
Drug: 20g SQ-LNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20g SQ-LNS without zinc and 5mg zinc tablet
Study: 26362661
Drug: 20g SQ-LNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20g SQ-LNS without zinc and placebo tablet
Study: 20848367
Drug: Oxygen cost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen cost (mL O(2)/kg/m)
Study: 17984403
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride (20 mg/d) with CBT
Study: 15771764
Drug: LAM (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM (lansoprazole 30 mg b.d., amoxicillin 1 g b.d., metronidazole 400 mg t.d.s.)
Study: 15771764
Drug: LAC (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (lansoprazole 30 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d.)
Study: 15771764
Drug: RMT (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMT (ranitidine bismuth citrate 400 mg b.d., metronidazole 400 mg t.d.s., tetracycline 500 mg q.d.s.)
Study: 9617511
Drug: Lisuride (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (0.3 mg daily for 12 weeks)
Study: 3297874
Drug: Control (cytostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (cytostatic drugs and/or surgery without BCG)
Study: 30358728
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral conjugated equine estrogens (0.625 mg/d)
Study: 27457964
Drug: Orteronel 300
Normalized name: Orteronel
DrugBank: Orteronel (DB12066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orteronel 300 mg twice daily
Study: 20133511
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil 1 mg twice daily
Study: 20133511
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg twice daily
Study: 20133511
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral treprostinil 1 mg twice daily and bosentan 125 mg twice daily
Study: 18675689
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication regimen (lansoprazole 30 mg twice daily, amoxicillin 750 mg twice daily, and clarithromycin 200 mg twice daily for a week)
Study: 18675689
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (no treatment for H pylori)
Study: 18448418
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg (P150) with ibuprofen 800 mg
Study: 18448418
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg (P75) with ibuprofen 800 mg
Study: 18448418
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg (D5) with ibuprofen 800 mg
Study: 15034644
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A intake (0.53 mg/day)
Study: 11399694
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group (n = 36) participated in a 6-week program of education (2 h weekly) and exercise (1 h weekly)
Study: 8369010
Drug: Ferro‐Folsan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferro‐Folsan (100 mg of ferrous‐II‐sulfate and 0.85 mg of folic acid)
Study: 29771077
Drug: Flupentixol melitracen
Normalized name: melitracen
DrugBank: Melitracen (DB13384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol melitracen (1 tablet/day) for 3 months
Study: 24491199
Drug: Mindfulness treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness treatment group (MTG)
Study: 22144668
Drug: Clopidogrel hydrogen
Normalized name: Clopidogrel hydrogen sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel hydrogen sulfate (CHS) 75 mg/d
Study: 22144668
Drug: Clopidogrel besylate
Normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel besylate (CB) 75 mg/d
Study: 17989536
Drug: Rapid protocols
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid protocols for venom immunotherapy
Study: 17989536
Drug: Venom immunotherapy
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venom immunotherapy in patients with mast cell diseases
Study: 17989536
Drug: New strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New strategies for venom immunotherapy (genetic engineering)
Study: 11259736
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading (75 g) in pregnant women
Study: 11259736
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose loading (75 g) in non-pregnant women
Study: 26632295
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia administered by students who practiced on the simulation model (experimental group, N=30)
Study: 23945891
Drug: Acetazolamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (25 mg/kg/day) started in the first 48 hours after admission
Study: 23945891
Drug: Acetazolamide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (25 mg/kg/day) administered after the first 48 hours
Study: 7264274
Drug: Topical diethylcarbamazine
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical diethylcarbamazine (DEC)
Study: 7264274
Drug: Yeast tablets
Normalized name: Azo Yeast Tablets
DrugBank: Yeast (DB11017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast tablets
Study: 28685204
Drug: Prasugrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (loading dose 20 mg, maintenance dose 3.75 mg/day for 7 days)
Study: 28685204
Drug: Prasugrel (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (maintenance dose 3.75 mg/day for 7 days)
Study: 28685204
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day after switching from prasugrel)
Study: 22520621
Drug: Resveratrol-rich grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol-rich grape supplement (resveratrol 8 mg)
Study: 22520621
Drug: Conventional grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional grape supplement lacking resveratrol
Study: 19525871
Drug: L reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L reuteri (1 x 10 CFU)
Study: 17544870
Drug: Sibutramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (15 mg/day for 12 weeks)
Study: 11438377
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg daily for 6 months)
Study: 11438377
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate depot (3.75 mg every 28 days for 6 months)
Study: 11438377
Drug: Post-treatment (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (3 months after termination of both treatments)
Study: 9053474
Drug: Salvage treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage treatments after MOPP-ABVD
Study: 9053474
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy re-treatment
Study: 9053474
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy or new regimens
Study: 8429117
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (bid)
Study: 30783676
Drug: TAK-003 (live-attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (live-attenuated tetravalent dengue vaccine candidate)
Study: 21289258
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg denosumab every 6 months for 24 months
Study: 21289258
Drug: Denosumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (after discontinuation)
Study: 21289258
Drug: Denosumab and
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab and Placebo (off-treatment phase)
Study: 16632297
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg zinc sulfate treatment
Study: 14754691
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg synthetic conjugated estrogens
Study: 14754691
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg synthetic conjugated estrogens
Study: 14754691
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg synthetic conjugated estrogens
Study: 10910019
Drug: Selective adsorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective adsorption (SA) followed by intravenous immunoglobulin (i.v. IgG)
Study: 10910019
Drug: Selective adsorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective adsorption (SA) using a tryptophan-linked polyvinyl alcohol gel adsorbent
Study: 8112969
Drug: Oral pefloxacin
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pefloxacin 400 mg
Study: 30928413
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5‐fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5‐fluorouracil])
Study: 30928413
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment (subgroup analysis)
Study: 25776729
Drug: Clonidine transdermal
Normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine transdermal patch (test formulation)
Study: 25776729
Drug: Clonidine transdermal
Normalized name: Clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine transdermal patch (reference formulation)
Study: 19114687
Drug: Radiotherapy (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (cumulative dose, 50 Gy)
Study: 15080820
Drug: Fexofenadine (FEX)
Normalized name: fexofenadine Oral Tablet [Wal-Fex]
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine (FEX) 180 mg once daily
Study: 10835090
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (betamethasone)
Study: 9258847
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of concentric and eccentric training (C‐E/‐E, n = 11)
Study: 3522723
Drug: Single vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaginal application of a suppository containing 10 mg of 9‐deoxo‐16‐PGE2
Study: 22376226
Drug: Vision restoration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision restoration therapy (VRT) combined with active tDCS
Study: 22376226
Drug: Vision restoration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision restoration therapy (VRT) paired with sham tDCS
Study: 19581542
Drug: Xylitol topical
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol topical oral syrup (2 xylitol [4.00-g] doses and 1 sorbitol dose) administered twice a day (Xyl-2x group)
Study: 19581542
Drug: Xylitol topical
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol topical oral syrup (3 xylitol [2.67-g] doses) administered thrice a day (Xyl-3x group)
Study: 19581542
Drug: Control syrup
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control syrup (1 xylitol [2.67-g] dose and 2 sorbitol doses)
Study: 11815975
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in older cohorts (age > 70 years)
Study: 6446314
Drug: Metronidazole 200
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 200 mg twice daily
Study: 6446314
Drug: Oxytetracycline 250
Normalized name: oxytetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytetracycline 250 mg twice daily
Study: 26863502
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (8 mL/h)
Study: 26863502
Drug: Automated hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated hourly boluses (8 mL/bolus)
Study: 22407438
Drug: Adolescent-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent-focused therapy (AFT)
Study: 17513814
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan 2.3 mg/m2/d on days 1 through 5 every 21 days
Study: 17513814
Drug: IV topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days